Ronald Dahl

25.9k total citations · 4 hit papers
321 papers, 13.4k citations indexed

About

Ronald Dahl is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Ronald Dahl has authored 321 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 207 papers in Physiology, 163 papers in Pulmonary and Respiratory Medicine and 100 papers in Immunology and Allergy. Recurrent topics in Ronald Dahl's work include Asthma and respiratory diseases (198 papers), Allergic Rhinitis and Sensitization (93 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (80 papers). Ronald Dahl is often cited by papers focused on Asthma and respiratory diseases (198 papers), Allergic Rhinitis and Sensitization (93 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (80 papers). Ronald Dahl collaborates with scholars based in Denmark, United States and United Kingdom. Ronald Dahl's co-authors include Per Venge, Niels Mygind, S. Rak, M. Iversen, C. Motala, Lars Peter Nielsen, Johannes Ring, Thomas A.E. Platts‐Mills, Thomas Bieber and Bobby Q. Lanier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Ronald Dahl

316 papers receiving 12.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003

2004 1.6k citations Ronald Dahl et al. Journal of Allergy and Clinical Immunology profile →
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy

2012 476 citations Huib A.M. Kerstjens, Ronald Dahl et al. profile →
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD

2014 406 citations Ronald Dahl, Peter M.A. Calverley et al. profile →
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

2012 376 citations Stephen R. Durham, W. Emminger et al. Journal of Allergy and Clinical Immunology profile →

Peers

Countries citing papers authored by Ronald Dahl

Since Specialization

Citations

This map shows the geographic impact of Ronald Dahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Dahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Dahl more than expected).

Fields of papers citing papers by Ronald Dahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Dahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Dahl. The network helps show where Ronald Dahl may publish in the future.

Co-authorship network of co-authors of Ronald Dahl

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Dahl. A scholar is included among the top collaborators of Ronald Dahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Dahl. Ronald Dahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response 2017 ·COPD Journal of Chronic Obstructive Pulmonary Disease ·(unknown), Camilla Steen Jensen, Mohamed S. Arredouani, Ronald Dahl, Morten Dahl	20
2	Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat ^® in Asthma Using Standardized Sample-Contamination Avoidance 2016 ·Journal of Aerosol Medicine and Pulmonary Drug Delivery ·Kai-Michael Beeh, Anne‐Marie Kirsten, Daniel Dusser, Ashish Sharma, Piet J.G. Cornelissen, Ralf Sigmund, Petra Moroni-Zentgraf, Ronald Dahl	19
3	Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial 2015 ·BMJ Open ·Ronald Dahl, Peter M.A. Calverley, Antonio Anzueto, Norbert Metzdorf, (unknown), Achim Mueller, Robert A. Wise, Daniel Dusser	8
4	Once-daily tiotropium Respimat (R) as add-on to at least medium- to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status 2014 ·Allergy ·Ronald Dahl, Eric D. Bateman, Thomas B. Casale, Emílio Pizzichini, (unknown), (unknown), Michael Engel, Ralf Sigmund, Petra Moroni-Zentgraf, Huib A.M. Kerstjens	2
5	Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Its Monocomponents: The BEACON Study 2014 ·CHEST Journal ·Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen, Donald Banerji	2
6	Once-daily QVA149 has a good safety profile in patients with COPD 2013 ·European Respiratory Journal ·Tobias Welte, Claus Vogelmeier, Ronald Dahl, Kenneth R. Chapman, (unknown), Rajendra Mehta, Peter D’Andrea, Hungta Chen, Donald Banerji	6
7	Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes 2013 ·European Respiratory Journal ·C. Franz Vogelmeier, Ronald Dahl, Anthony D’Urzo, Hungta Chen, Yulia Green, Donald Banerji	1
8	QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD 2013 ·European Respiratory Journal ·Ronald Dahl, Nicola Gallagher, Yulia Green, (unknown), Hungta Chen, Peter D’Andrea, Vijay Alagappan, Donald Banerji	9
9	Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study 2013 ·European Respiratory Journal ·Ronald Dahl, Dalal Jadayel, Vijay Alagappan, Hungta Chen, Donald Banerji	2
10	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article 2010 ·Journal of Allergy and Clinical Immunology ·Philippe‐Jean Bousquet, Moisés A. Calderón, Pascal Demoly, Désirée Larenas‐Linnemann, Giovanni Passalacqua, Claus Bachert, Jan Brożek, Giorgio Walter Canonica, Thomas B. Casale, João Fonseca, Ronald Dahl, Stephen R. Durham, (unknown), Margitta Worm, U. Wahn, Torsten Zuberbier, Holger J. Schünemann, Jean Bousquet	37
11	Sustained, disease-modifying effect of grass allergen tablet immunotherapy 1 year after completion of treatment 2009 ·Data Archiving and Networked Services (DANS) ·Stephen R. Durham, Ronald Dahl, Alexander Kapp, Giselda Colombo, J. de Monchy, S. Rak, B.J. Riis, W. Emminger	3
12	Continuous clinical efficacy and progressive immunological effect of long-term specific immunotherapy with the ALK grass allergen tablet : Findings from a 3-year randomised adult trial 2008 ·Allergy ·W. Emminger, Ronald Dahl, Alexander Kapp, Giselda Colombo, J. de Monchy, S. Rak, (unknown), (unknown)	2
13	Delay in diagnosis of lung cancer in general practice. 2006 ·Europe PMC (PubMed Central) ·(unknown), Torben Palshof, Ronald Dahl, Peter Vedsted, Frede Olesen	110
14	Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease 2001 ·American Journal of Respiratory and Critical Care Medicine ·Ronald Dahl, (unknown), Dariusz Nowak, В Е Ноников, (unknown), Moira H. Thomson, Denise Till, Giovanni Della Cioppa	275
15	Therapeutic Ratio of Inhaled Corticosteroids in Adult Asthma 2000 ·American Journal of Respiratory and Critical Care Medicine ·Lars Peter Nielsen, Ronald Dahl	49
16	Eosinophil and Neutrophil Activity in Asthma in a One-Year Trial With Inhaled Budesonide. The Impact of Smoking 1996 ·American Journal of Respiratory and Critical Care Medicine ·B. Pedersen, Ronald Dahl, Rolf O. Karlstrom, (unknown), Per Venge	140
17	Subcutaneous Administration of Hyaluronan Reduces the Number of Infectious Exacerbations in Patients With Chronic Bronchitis 1996 ·American Journal of Respiratory and Critical Care Medicine ·Per Venge, B. Pedersen, Lena Håkansson, Roger Hällgren, Gert Lindblad, Ronald Dahl	36
18	Serum eosinophilic cationic protein and lactoferrin related to smoking history and lung function 1994 ·European Respiratory Journal ·(unknown), Bente Klarlund Pedersen, (unknown), Per Venge, Ronald Dahl	21
19	Nebulized terbutaline and positive expiratory pressure in chronic obstructive pulmonary disease 1991 ·Erika Frischknecht Christensen, Ole Nørregaard, Ronald Dahl	2
20	Number of mites in stored grain, straw and hay related to the age of the substrate (Acari). 1991 ·T.E. Hallas, M. Iversen, J. Korsgaard, Ronald Dahl	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact